Updated Efficacy/Safety Data from the Phase 2 Study of Alectinib in ALK–Positive Non–Small–Cell Lung Cancer

Updated Efficacy/Safety Data from the Phase 2 Study of Alectinib in ALK–Positive Non–Small–Cell Lung Cancer

VJOncology

2 years
321 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Shirish Gadgeel, MD, from Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, provides us with updated information on a North American study (NP28761) evaluating alectinib in patients with ALKpositive NonSmallCell Lung Cancer (NSCLC) who are resistant to crizotinib, the first line ALK inhibitor. Based on results from several studies, alectinib has been approved in the US and Japan for the treatment of patients who have progressed on or are intolerant to crizotinib. Shirish Gadgeel gives us an overview of the results from the updated study that had a longer 17-month follow-up than the primary analysis. The study showed that the response rate for alectinib was about 52%, the response rate in patients with measurable CNS metastases was 75%, the medium progression-free survival (PFS) was approximately 8.5 months and the overall survival of patients enrolled on this trail was about 22 months. He mentions how this study confirms the activity already observed with alectinib in ALK-positive NSCLC patients previously treated with crizotinib and the next step is to wait for results of the global on-going ALEX study, which is comparing alectinib to crizotinib as an initial first-line treatment for ALK-Positive NSCLC patients. Recorded at the 2016 World Congress of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.
Up Next Autoplay
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
0 Views
Cancer-News 58 minutes
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
0 Views
kidneycancer 2 hours
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
0 Views
kidneycancer 3 hours
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
1 Views
kidneycancer 22 hours
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
4 Views
Cancer-News 1 day
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 1 day
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
3 Views
kidneycancer 1 day
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
2 Views
Cancer-News 1 day
Management of Clinical Cases in Kidney Cancer
Management of Clinical Cases in Kidney Cancer
Category: Kidney Cancer
4 Views
kidneycancer 2 days
Kidney Cancer Program & SPORE
Kidney Cancer Program & SPORE
Category: Kidney Cancer
1 Views
kidneycancer 2 days